enzalutamide,talazoparib
astellas,pfizer
['talapro,2', 'brca', 'talazo', 'crpc', 'talapro-2']
dr. karin fizazi presented the results of talapro-2 hrr deficient: ph3 trial comparing enza+talazoparib vs. enza+placebo in mcrpc with hrr deficiency. significant improvement in rpfs but not yet in os. strong effect in brca mutated patients. #asco23 
Medical oncologist at @BPorgbr. Former fellow of GU oncology @DanaFarber @Harvard @MOCbrasil. #GUcancer